The Clorox Company (CLX) Market Cap & Valuation Ratios
The Clorox Company (CLX) has a market cap of $10.4B, a trailing P/E of 17.9 and a price-to-sales ratio of 1.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLXThe Clorox CompanyFollow CLX — free
—
Price chart with a free account
- Market cap
- 10.4B
- P/E TTM
- 17.9
- Dividend yield
- 5.7%
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Peers
household & personal products · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CLX | 10 | 17.9 | 2.3 | 13.2 | 3.9% | -5% | 14% | 18% |
| CL | 75 | 37.2 | 3.9 | 21.6 | 5.1% | +5% | 15% | 31% |
| EL | 39 | — | 2.9 | 27.4 | 3.3% | +5% | 5% | 8% |
| KVUE | 38 | 22.5 | 2.9 | 14.1 | 5.1% | +2% | 17% | 11% |
| KMB | 37 | 18.7 | 2.5 | 13.0 | 5.0% | +0.7% | 15% | 22% |
| CHD | 25 | 33.7 | 4.3 | 20.0 | 4.5% | +3% | 17% | 14% |
| ELF | 6.7 | 114.2 | 4.1 | 32.9 | 4.2% | +31% | 7% | 7% |
| IPAR | 3.7 | 22.0 | 2.4 | 12.8 | 6.7% | +3% | 17% | 22% |
| COTY | 2.8 | — | 1.0 | 14.3 | 12.2% | -1% | -1% | -1% |
| NWL | 2.3 | — | 1.0 | 14.8 | 5.2% | -2% | 2% | 2% |
| SPB | 1.8 | 25.2 | 0.8 | 10.2 | 15.9% | +0.8% | 4% | 4% |
| Median of these 10 | 25.2 | 2.7 | 14.5 | 5.1% | +2% | 11% | 9% |
P/E 17.9 vs. a peer median of 25.2; EV/Sales 2.3 vs. 2.7. CLX's own P/E sits at the 14th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesEL and COTY and NWL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
The Clorox Company — questions
- What is The Clorox Company's market cap?
- $10.4B.
- What is The Clorox Company's P/E ratio?
- 17.9 on trailing twelve-month earnings to 2026-06-30.
- What is The Clorox Company's price-to-sales ratio?
- 1.6.
Every figure on this page comes from The Clorox Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.